Rezultati - Balusu, Ramesh
- Showing 1 - 20 results of 20
-
1
-
2
C/EBPβ-mediated transcriptional regulation of bcl-xl gene expression in human breast epithelial cells in response to cigarette smoke condensate od Connors, Shahnjayla K., Balusu, Ramesh, Kundu, Chanakya N., Jaiswal, Aruna S., Gairola, C. Gary, Narayan, Satya
Izdano 2008Text -
3
-
4
A NOVEL TETRAZOLE ANALOGUE OF RESVERATROL IS A POTENT ANTICANCER AGENT od Bommagani, Shobanbabu, Penthala, Narsimha Reddy, Balasubramaniam, Meenakshisundaram, Kuravi, Sudhakiranmayi, Caldas-Lopes, Eloisi, Guzman, Monica L., Balusu, Ramesh, Crooks, Peter A.
Izdano 2018Text -
5
CDC37 as a novel target for the treatment of NPM1-ALK expressing anaplastic large cell lymphomas od Kuravi, Sudhakiranmayi, Parrott, Elizabeth, Mudduluru, Giridhar, Cheng, Janice, Ganguly, Siddhartha, Saunthararajah, Yogen, Jensen, Roy A., Blagg, Brian S., McGuirk, Joseph P., Balusu, Ramesh
Izdano 2019Text -
6
Heat shock protein 90 inhibition depletes TrkA levels and signaling in human acute leukemia cells od Rao, Rekha, Nalluri, Srilatha, Fiskus, Warren, Balusu, Ramesh, Joshi, Atul, Mudunuru, Uma, Buckley, Kathleen M., Robbins, Kelly, Ustun, Celalettin, Reuther, Gary W., Bhalla, Kapil N.
Izdano 2010Text -
7
Targeting NPM1 represents a rationale strategy for radiosensitization od Sekhar, Konjeti R., Benamar, Mouadh, Venkateswaran, Amudhan, Sasi, Soumya, Penthala, Narsimha R, Crooks, Peter A, Hann, Stephen R, Geng, Ling, Balusu, Ramesh, Abbas, Tarek, Freeman, Michael L.
Izdano 2014Text -
8
Superior efficacy of a combined epigenetic therapy against human Mantle Cell Lymphoma (MCL) cells od Fiskus, Warren, Rao, Rekha, Balusu, Ramesh, Ganguly, Siddhartha, Tao, Jianguo, Sotomayor, Eduardo, Mudunuru, Uma, Smith, Jacqueline E., Hembruff, Stacey L., Atadja, Peter, Marquez, Victor E., Bhalla, Kapil
Izdano 2012Text -
9
Role of C/EBP homologous protein (CHOP) in Panobinostat-mediated potentiation of Bortezomib-induced lethal ER stress in Mantle Cell Lymphoma cells od Rao, Rekha, Nalluri, Srilatha, Fiskus, Warren, Savoie, Andrew, Buckley, Kathleen M, Ha, Kyungsoo, Balusu, Ramesh, Joshi, Atul, Coothankandaswamy, Veena, Tao, Jianguo, Sotomayor, Eduardo, Atadja, Peter, Bhalla, Kapil N.
Izdano 2010Text -
10
Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells od Fiskus, Warren, Buckley, Kate, Rao, Rekha, Mandawat, Aditya, Yang, Yonghua, Joshi, Rajeshree, Wang, Yongchao, Balusu, Ramesh, Chen, Jianguang, Koul, Sanjay, Joshi, Atul, Upadhyay, Sunil, Atadja, Peter, Bhalla, Kapil N.
Izdano 2009Text -
11
Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells od Fiskus, Warren, Verstovsek, Srdan, Manshouri, Taghi, Rao, Rekha, Balusu, Ramesh, Venkannagari, Sreedhar, Nalabothula, Narasimha Rao, Ha, Kyungsoo, Smith, Jacqueline E., Hembruff, Stacey, Abhyankar, Sunil, McGuirk, Joseph, Bhalla, Kapil N.
Izdano 2011Text -
12
Co-treatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells od Fiskus, Warren, Wang, Yongchao, Joshi, Rajeshree, Rao, Rekha, Yang, Yonghua, Chen, Jianguang, Kolhe, Ravindra, Balusu, Ramesh, Eaton, Kelly, Lee, Pearl, Ustun, Celalettin, Jillella, Anand, Buser, Carolyn A., Peiper, Stephen, Bhalla, Kapil
Izdano 2008Text -
13
Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human Mantle Cell L... od Rao, Rekha, Lee, Pearl, Fiskus, Warren, Yang, Yonghua, Joshi, Rajeshree, Wang, Yongchao, Buckley, Kate, Balusu, Ramesh, Chen, Jianguang, Koul, Sanjay, Joshi, Atul, Upadhyay, Sunil, Tao, Jianguo, Sotomayor, Eduardo, Bhalla, Kapil N.
Izdano 2009Text -
14
Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells od Fiskus, Warren, Wang, Yongchao, Sreekumar, Arun, Buckley, Kathleen M., Shi, Huidong, Jillella, Anand, Ustun, Celalettin, Rao, Rekha, Fernandez, Pravina, Chen, Jianguang, Balusu, Ramesh, Koul, Sanjay, Atadja, Peter, Marquez, Victor E., Bhalla, Kapil N.
Izdano 2009Text -
15
Preclinical evaluation of gilteritinib on NPM1-ALK driven Anaplastic Large Cell Lymphoma Cells od Kuravi, Sudhakiranmayi, Cheng, Janice, Fangman, Gabrielle, Polireddy, Kishore, McCormick, Sophia, Lin, Tara L., Singh, Anurag K., Abhyankar, Sunil, Ganguly, Siddhartha, Welch, Danny R., Jensen, Roy A., McGuirk, Joseph P., Balusu, Ramesh
Izdano 2021Text -
16
Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1 od Balusu, Ramesh, Fiskus, Warren, Rao, Rekha, Chong, Daniel G., Nalluri, Srilatha, Mudunuru, Uma, Ma, Hongwei, Chen, Lei, Venkannagari, Sreedhar, Ha, Kyungsoo, Abhyankar, Sunil, Williams, Casey, McGuirk, Joseph, Khoury, Hanna Jean, Ustun, Celalettin, Bhalla, Kapil N.
Izdano 2011Text -
17
Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neopla... od Wang, Yongchao, Fiskus, Warren, Chong, Daniel G., Buckley, Kathleen M., Natarajan, Kavita, Rao, Rekha, Joshi, Atul, Balusu, Ramesh, Koul, Sanjay, Chen, Jianguang, Savoie, Andrew, Ustun, Celalettin, Jillella, Anand P., Atadja, Peter, Levine, Ross L., Bhalla, Kapil N.
Izdano 2009Text -
18
Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients od Mushtaq, Muhammad Umair, Shahzad, Moazzam, Chaudhary, Sibgha Gull, Luder, Mary, Ahmed, Nausheen, Abdelhakim, Haitham, Bansal, Rajat, Balusu, Ramesh, DeJarnette, Shaun, Divine, Clint, Kribs, Robert, Shune, Leyla, Singh, Anurag K., Ganguly, Siddhartha, Abhyankar, Sunil H., McGuirk, Joseph P.
Izdano 2021Text -
19
Functional characterization of NPM1–TYK2 fusion oncogene od Kuravi, Sudhakiranmayi, Baker, Riley W., Mushtaq, Muhammad Umair, Saadi, Irfan, Lin, Tara L., Vivian, Carolyn J., Valluripalli, Anusha, Abhyankar, Sunil, Ganguly, Siddhartha, Cui, Wei, Elenitoba-Johnson, Kojo S. J., Welch, Danny R., Jensen, Roy A., Saunthararajah, Yogen, McGuirk, Joseph P., Balusu, Ramesh
Izdano 2022Text -
20
Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates od Gu, Xiaorong, Ebrahem, Quteba, Mahfouz, Reda Z., Hasipek, Metis, Enane, Francis, Radivoyevitch, Tomas, Rapin, Nicolas, Przychodzen, Bartlomiej, Hu, Zhenbo, Balusu, Ramesh, Cotta, Claudiu V., Wald, David, Argueta, Christian, Landesman, Yosef, Martelli, Maria Paola, Falini, Brunangelo, Carraway, Hetty, Porse, Bo T., Maciejewski, Jaroslaw, Jha, Babal K., Saunthararajah, Yogen
Izdano 2018Text